6IO Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthA strong liquidity position and zero debt provide durable financial flexibility to fund product launches, clinical programs and international expansion without immediate refinancing risk. This supports execution through the current unprofitable transition and cushions cash burn while management scales operations.
Product DifferentiationLonger device useful life and superior serviceability create a structural competitive edge: larger installed base, stronger replacement/accessory demand and higher lifetime value per patient. Combined with growing outcomes data, this supports premium positioning and more durable margins over time.
International ExpansionMeaningful international growth diversifies revenue away from a weak U.S. channel and taps higher-growth markets via tenders and HME relationships. Regional expansion can smooth seasonality and create sustainable multi-geography revenue streams supporting long-term top-line resilience.
Bears Say
Negative Cash FlowPersistently negative free cash flow and sharply worsening FCF growth reduce the firm's ability to self-fund working capital and growth. Even with cash on hand, ongoing cash burn pressures capital allocation, limits optionality for investments, and risks depleting reserves if profitability doesn't improve.
Profitability DeficitDespite margin improvement, sustained GAAP losses and negative adjusted EBITDA signal the business hasn't reached durable earnings power. Continued operating losses constrain reinvestment, reduce ability to build reserves, and prolong dependence on liquidity while the company scales new products.
U.S. Channel HeadwindsStructural conversion in the U.S. market is pressuring direct-to-consumer and rental channels, eroding a historically stable revenue stream. Weakness in U.S. sales and rentals reduces recurring revenue predictability and forces greater reliance on international rollouts and new products to restore long-term growth.
Inogen News
6IO FAQ
What was Inogen’s price range in the past 12 months?
Currently, no data Available
What is Inogen’s market cap?
Inogen’s market cap is CHF141.24M.
When is Inogen’s upcoming earnings report date?
Inogen’s upcoming earnings report date is Aug 06, 2026 which is today.
How were Inogen’s earnings last quarter?
Inogen released its earnings results on May 07, 2026. The company reported -CHF0.243 earnings per share for the quarter, missing the consensus estimate of -CHF0.229 by -CHF0.014.
Is Inogen overvalued?
According to Wall Street analysts Inogen’s price is currently Undervalued.
Does Inogen pay dividends?
Inogen does not currently pay dividends.
What is Inogen’s EPS estimate?
Inogen’s EPS estimate is -0.12.
How many shares outstanding does Inogen have?
Currently, no data Available
What happened to Inogen’s price movement after its last earnings report?
Inogen reported an EPS of -CHF0.243 in its last earnings report, missing expectations of -CHF0.229. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Inogen?
Currently, no hedge funds are holding shares in CH:6IO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inogen Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF9.69 (― Upside)
CHF9.69 (― Upside)
Blogger Sentiment
Bullish
CH:6IO Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-3.54%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-7.29%
Trailing 12-Months
Company Description
Inogen
Inogen, Inc. operates as a medical technology enterprise dedicated to designing, fabricating, and distributing oxygen concentration equipment. These cutting-edge devices are engineered to provide continuous oxygen support for patients managing persistent respiratory conditions. The company's diverse product range features the popular portable Inogen One, which efficiently draws oxygen from the surrounding atmosphere to offer an independent supply, alongside stationary Inogen At Home concentrators, Tidal Assist Ventilators, and various associated accessories. Inogen serves a broad clientele, including individual patients, medical professionals, and insurance providers, both domestically in the United States and globally. Furthermore, the company facilitates direct equipment rentals to patients. Founded in 2001, Inogen, Inc. is headquartered in Goleta, California.
6IO Company Deck
6IO Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call reflects a company in transition: solid top-line growth driven by international expansion, strong unit volume gains, new product launches with encouraging early clinical and commercial signals, and a healthy balance sheet. Offsetting these positives are meaningful near-term headwinds in the U.S. market (declining direct and rental sales), higher operating losses due to accelerated R&D and commercial investments, and reliance on a FX tailwind. Management reaffirmed full-year guidance and expects EBITDA improvement, but several financial metrics remain under pressure in the near term.View all CH:6IO earnings summaries